Positive developments on many fronts

“

In Q2, strong growth continued in all major divisions, and in many areas the growth exceeded our expectations. We also continued to implement our growth strategy with positive developments on many fronts. What warms me most is that our work has an impact on the lives of growing number of patients as the net sales increase comes from several different products - a fact of which we all at Orion can be proud of.

Published on 18 July 2025

"In April–June 2025, our net sales increased by 26.9 percent to EUR 416.5 (328.2) million and operating profit increased by 58.9 percent to EUR 104.6 (65.8) million.

In Q2, strong growth continued in all major divisions, and in many areas the growth exceeded our expectations. Operating profit increased faster than net sales mainly due to the growth of Nubeqa® royalties. This good development is anticipated to continue during the remainder of the year which is why we upgraded our outlook for 2025 in early July.

Once again, the performance of Nubeqa® was outstanding with both royalty income and product sales showing very strong growth. The Branded Products and Animal Health divisions also reported double-digit growth. Growth in Branded Products and Animal Health was generated from a variety of different products. This reflects the strength of our diverse product portfolio in these divisions. The same applies to the Generics and Consumer Health business division whose growth was above the average generic market growth. What warms me most is that our work has an impact on the lives of growing number of patients as the net sales increase comes from several different products - a fact of which we all at Orion can be proud of.

In Q2, we continued to implement our growth strategy with positive developments on many fronts. This includes, just to mention a few, opening  our new research & development centre in Cambridge, UK, filling certain key roles with new recruitments in Innovative Medicines and Research & Development, as well as some new and expanded collaboration and licence agreements in different business areas. Moreover, our collaborator MSD expanded the opevesostat development program to women's cancers.

In connection with our Capital Markets Day in May, we added to our key clinical development projects three clinical trials which are conducted by our collaborators with molecules invented by Orion.  Furthermore, we received positive news in June when the U.S. Food and Drug Administration (FDA) approved, and the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended darolutamide in combination with androgen deprivation therapy for use in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

We are committed and dedicated to our growth strategy, and after a strong H1, it is easy to move forward into H2 with confidence.”